Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 13/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 12/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069834 | 1.00 | NR1I2 (0.70) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL1073422 | 0.84 | NR1I2 (0.69) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL1073431 | 0.84 | NR1I2 (0.69) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL1069832 | 0.83 | NR1I2 (0.72) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL1069239 | 0.82 | NR1I2 (0.71) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL13092840 | 0.81 | NR1I2 (0.83) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL3063186 | 0.81 | NR1I2 (0.71) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL3063687 | 0.81 | NR1I2 (0.71) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL3063691 | 0.81 | NR1I2 (0.71) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 | |
| SCHEMBL3063281 | 0.81 | P2RX3 (1.00) | NR1I2P2RX3P2RX2CYP2C9UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215048-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8461185-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110003822-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003822-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | NR1I2 598/4885P2RX3 1/4885P2RX2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.